Recently,ChinaVenture Releases "CV Awards·Sharp Company 100 List", focusing on innovation tracks such as artificial intelligence, robotics, low-altitude economy, commercial aerospace, and healthcare.METiS TechBio has been successfully selected thanks to its outstanding technological innovation and strong growth potential.Ranked alongside hard tech companies in Hangzhou such as Unitree Robotics and DeepRobotics.
Capital Boosts Technological Innovation, Innovative Enterprises Continue to RiseAs a highly influential list in the industry, this is the fifth year that China Venture has released the "CV Awards · Top 100 Razor Companies List." Based on the activity of growth enterprises in the capital markets within these sectors, companies with high financing activity and strong growth potential are selected and named with the word "Razor." Razor symbolizes sharpness, derived from metal with a cutting sound, representing boldness and relentless forward momentum in a vast world full of diverse phenomena. Committed to ideals and focused on the present, China Venture observes the development journey of technological innovation from the perspective of capital, making the future trajectory more attainable.
In recent years, the global pharmaceutical industry's attention to cutting-edge technologies such as RNA drugs, gene editing, cell and gene therapies has continued to rise. Efficient and safe delivery systems have become one of the key factors in breaking through industry bottlenecks. Against this trend, METiS TechBio has achieved a leading edge in technological innovation and industrial application with its self-developed AI-driven nanomedicine delivery platform.
AI-Driven Nano-Delivery, Building Industry-Leading Technical Barriers
As a world-leading "AI + nanomaterials" drug delivery technology platform, METiS TechBio independently developed innovative artificial intelligence computational simulation algorithms from scratch for ionizable lipid generation and design, LNP nanomaterial simulation, and more, despite the lack of open-source datasets and delivery-related algorithms. By integrating high-throughput experimental techniques and animal validation platforms, METiS TechBio has built unique data and algorithm barriers to facilitate the efficient delivery of RNA drugs, mRNA vaccines, and gene-editing therapies.Among them, the company's pioneering multi-organ targeted delivery technology has achieved highly efficient delivery to multiple organs such as the heart, muscles, and brain. The delivery efficiency in organs like the liver and lungs is more than 20 times higher than the industry standard, providing a breakthrough solution for the precise delivery of RNA drugs and filling the technical gap in the industry.Global Collaboration Layout: Driving Industry Transformation
In the rapidly developing biopharmaceutical sector, METiS TechBio consistently maintains an open and collaborative stance. It has established in-depth partnerships with over 20 of the world's leading pharmaceutical companies and biotech firms to jointly advance the research, development, and commercialization of innovative drugs. Meanwhile, the company has cumulatively raised $300 million in financing, with strong recognition from the capital markets further affirming its technological innovation capabilities and promising future prospects.Currently, China's biotech sector is entering the "DeepSeek Moment," a new phase of asset revaluation driven by technological innovation. With breakthroughs in AI, nanotechnology, and biopharmaceuticals, innovative companies are facing unprecedented market opportunities. METiS TechBioAlsoWill continue to deepen the application of AI and nanomaterials in the field of drug delivery, collaborate with global partners to bring more efficient and safer treatment solutions to patients worldwide.
Learn More About METiS TechBio
